Predict your next investment

Venture Capital
dievini.com

See what CB Insights has to offer

Investments

23

Portfolio Exits

4

About dievini Hopp BioTech Holding & Co.

dievini Hopp BioTech Holding & Co. is the life sciences investment firm of SAP co-founder Dietmar Hopp. Led by Friedrich von Bohlen and Christof Hettich, dievini focuses on oncology, CNS, cell-based therapies and personalized medicine. dievini's approach is entrepreneurially driven, with the goal of building organizations that create and support synergies between therapeutic and personalized medicine approaches. dievini and the Grand Duchy of Luxembourg are collaborating in pursuit of this common goal.

dievini Hopp BioTech Holding & Co. Headquarter Location

Johann Jakob Astor-Str. 57

69190,

Luxembourg

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing dievini Hopp BioTech Holding & Co.

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find dievini Hopp BioTech Holding & Co. in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

dievini Hopp BioTech Holding & Co. Investments

23 Investments

dievini Hopp BioTech Holding & Co. has made 23 investments. Their latest investment was in Immatics Biotechnologies as part of their PIPE on July 7, 2020.

CBI Logo

dievini Hopp BioTech Holding & Co. Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/2/2020

PIPE

Immatics Biotechnologies

$104M

No

AT Impf, Federated Hermes, Perceptive Advisors, Redmile Group, RTW Investments, Sphera Funds, and Wellington Partners

1

10/11/2018

Series F

Novaliq

$53M

No

3

10/4/2017

Series E

Immatics Biotechnologies

$58M

No

Amgen, AT Impf, and Wellington Partners

3

11/16/2015

Unattributed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

11/3/2015

Series F

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/2/2020

10/11/2018

10/4/2017

11/16/2015

11/3/2015

Round

PIPE

Series F

Series E

Unattributed VC - II

Series F

Company

Immatics Biotechnologies

Novaliq

Immatics Biotechnologies

Subscribe to see more

Subscribe to see more

Amount

$104M

$53M

$58M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

AT Impf, Federated Hermes, Perceptive Advisors, Redmile Group, RTW Investments, Sphera Funds, and Wellington Partners

Amgen, AT Impf, and Wellington Partners

Sources

1

3

3

10

10

dievini Hopp BioTech Holding & Co. Portfolio Exits

4 Portfolio Exits

dievini Hopp BioTech Holding & Co. has 4 portfolio exits. Their latest portfolio exit was CureVac on August 14, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/14/2020

IPO

$991

8

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

8/14/2020

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

8

10

10

10

dievini Hopp BioTech Holding & Co. Acquisitions

2 Acquisitions

dievini Hopp BioTech Holding & Co. acquired 2 companies. Their latest acquisition was Novaliq GmbH Germany on January 01, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/1/2017

Series C

$36.22M

Acquired

1

7/17/2014

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/1/2017

7/17/2014

Investment Stage

Series C

Companies

Subscribe to see more

Valuation

Total Funding

$36.22M

$99M

Note

Acquired

Subscribe to see more

Sources

1

10

dievini Hopp BioTech Holding & Co. Team

3 Team Members

dievini Hopp BioTech Holding & Co. has 3 team members, including current Managing Partner, Friedrich von Bohlen.

Name

Work History

Title

Status

Friedrich von Bohlen

Managing Partner

Current

Friedrich von Bohlen und Halbach

Managing Partner

Current

Matthias Loehr

Managing Director

Current

Name

Friedrich von Bohlen

Friedrich von Bohlen und Halbach

Matthias Loehr

Work History

Title

Managing Partner

Managing Partner

Managing Director

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.